Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hey Tony abandon ship and let someone else add value to the sp
at least we cant go down more than 2 points
I guess there are problems with the science.
Equal you mentioned we havent heard any negative news about the science.
Have we heard any positive news about the science?
What happened to our pending deal with astra?
Why the silence for nearly a year?
You can rationalize anything.
How about Cantors 21.50 valuation?
What makes you think that the science is sound?
One good thing
We can go much lower!
They sold $20 million and lost over $20 million in share price value from closing price yesterday. Genius move!
50,000 shares all Nooooooooo
THE MARKET MAKERS 21.00 TARGET PRICE IS MEANINGLESS
Easy you are missing one fact..
their clinical data was good and ours in yet to be proven.
Thanks Tony for the enhanced stockholder value.
Presently down 70% since you took over.
If Lombardo has not been able to strike any deal over the last seven months for our late stage AXAL program or for HOT or HER2, that would be disappointing (and what the market seems to be pricing) and it would likely mean one of two things, neither of which is good: 1) Lombardo is past his prime and not effective, or 2) there is no demand among potential partners to strike a monetary deal with us on any of our franchises. I'm not sure which is worse - probably the second bullet point, because that reflects our platform and if there is no demand currently with M&A on fire and billions coming home in repatriated biotech cash, then maybe we are overestimating the effectiveness of our platform or given all the management mis-steps other technologies are surpassing us.
SOUND DEDUCTION!
Prepared for a negative event???
That’s all we have had for the past three years
this was posted on facebook page and sums it up
Advaxis Plans Since Tony "the deal maker" Lombardo took over:
MGT'S FAILURES RE 4 FRANCHISES
-Franchise One: HPV- Associated Cancers
-- Continue our commitment to commercializing axalimogene filolisbac: NO DEALS, FAIL
-- Completion of the MAA submission for conditional approval in Europe is on track for year end. FAILED
-- Enrollment continues in eight countries for AIM2CERV to evaluate axalimogene filolisbac as an adjuvant therapy in patients with high-risk locally advanced cervical cancer. CRICKETS, NO UPDATES
-- Collaboration with AstraZeneca on the Phase 2 combination trial with durvalumab in cervical and head and neck cancers is ongoing and continues to enroll. COLLAPSED
-- The combination trial with ADXS-DUAL and BMS's nivolumab for the treatment of women with persistent, recurrent or metastatic cervical cancer will be initiated in 1H 2018. This program will provide a second registrational opportunity in cervical cancer. CRICKETS, NO UPDATES
-- Given the promising early data in head and neck and anal cancers, Advaxis is actively pursuing opportunities to continue development through investigator-sponsored trials (ISTs) or other third-party approaches. ABANDONED, FAIL
2. Franchise Two: Prostate Cancer
-- Preliminary data presented at the 3rd International Cancer Immunotherapy Conference suggests that ADXS-PSA shows monotherapy activity in prostate cancer that is associated with a distinct immunologic and gene expression pattern. The ongoing trial, ADXS-PSA: Phase 1/2 Study (Keynote-046), evaluates ADXS-PSA as monotherapy and in combination with Merck's pembrolizumab. The clinical benefit in prostate cancer could be a significant value creator to expand the Lm platform into the prostate cancer market. CRICKETS, NO UPDATE AND NO DEAL WITH MERCK
-- In addition, the company is actively developing an additional product for prostate cancer, currently in preclinical testing, which could complement ADXS-PSA. CRICKETS, NO UPDATE
3. Franchise Three: Personalized Therapies Targeting Neoantigens
-- ADXS-NEO, in partnership with Amgen Inc., has the potential to be a major step forward in personalized medicine. First patient dosed is expected in 1H 2018. FAILED TO HIT MILESTONE, PROGRAM DELAYED INDEFINITELY
-- The initial tumor types for ADXS-NEO are metastatic microsatellite stable colon, head and neck, and non-small cell lung cancers. NONE STARTED
4. Franchise Four: Targeting Shared Hotpot Mutations and Tumor Associated Antigens-- Advancement of the proprietary ADXS-HOT preclinical program will expand Lm Technology into multiple products targeting several of the most common cancers. FAIL, NO HOT DEALS
-- Advaxis expects to file INDs for the first HOT products in 2018. CRICKETS, NO UPDATE
As part of its portfolio refinement, the company has determined it will not pursue further clinical study of ADXS-HER2 at this time, but remains open to ISTs or licensing opportunities. FAIL, NO DEALS
"We believe that focusing on these four franchises gives us the greatest opportunity to increase shareholder value and have a significant impact on patients and their families," said Lombardo. "Our excitement about the clinical potential of our Lm Technology is balanced by focus and fiscal discipline." FISCAL DISCIPLINE??? FAIL
VOTE NO! TO SHARE DILUTION
what day is the meeting?
That 4% that went to Dan was hush money not to reveal the dirty business going on with Adage. Better known here as the manipulators.
Reading these posts is like listening to the music playing on the titanic before it sunk.
Hornet
You are on target and speak for most of this board
K you listed secondary signs of a bo.
Why doesn’t management give it to Goldman to sell and announce it?
Sure not acting like a bo company.
The silence and execution of this company needs to change immediately
What about the new year theory?
Or the change of ceo theory?
Or the Bristol theory?
We had a favorable article come out yesterday why didn’t adxs showcase it?
It’s almost as if the people in charge want this price to be surpressed
It’s real comforting to know that I own more shares in adxs than Goldman sacks
Sandman
Framed very well.
Hey temporary Tony
Where is the enhanced value?
What happened to 66% of the sp since you came?
Where is any information over the past 9 months either positive or negative?
Where is your vision?
This isn’t like selling e-z contrast material.
What have you accomplished in the last 9 months?
A rising biotech with a shrinking sp
I am in
Will send you my phone number
Count me in!
Sitting with too many shares now.
It will be nice to also meet some of the pumpers here at the meeting
Good post
So let’s look what wall streets sharks and whales are saying about our adxs.
They are all voting with their feel and selling
Why?
Yup
Lombordo sure knows how to enhance share holder value we are down 70% since he took over.
Give him more time ?????
Fidelity and the other tuts knew these results before they were reported.
Spot on hornet
We need to get out of this death spiral
Big phony sure knows how to increase shareholder value.
Within hours stock plunges 15% after getting approval of their first drug.
Something is terribly wrong here.
Show me!!!!
Big difference between talking it and walking it .
So far Tony hasn’t done a thing to help increase value.
Dream on!
You can put lipstick on a pig
But it’s still a pig
This is dead money
Down too much to take the loss!
And at 3 not much more to loose
You were screaming buy at 12 10 8 6 4
So if we had clinical results half as good as kites
Stability at the top with a ceo who truly was concerned about investor value
A board that protected shareholder concerns
If all the above would be true could the manipulators be able to manipulate?
That could be a solution hornet and stop this nightmare.
What do you see?
You don’t know what you don’t know.
Time to put your Pom poms down and look at the sp